Such heterogeneity was reported before, but the main focus was on the MAPK pathway and melanoma-related oncogenic pathways and tumor suppressors, such as PI3K, PTEN, AKT, and CDKN2A [27], or amplification of BRAF and mutations of the RAS family [12,28]. This evidence concerns the gene CDKN2A and neoplasm.